Ipamorelin vs MK-677: Oral vs Injectable, and What the Community Actually Switches To (2026)
The honest one-line answer: this is not really a "which is stronger" question, it is a route-and-rhythm question. MK-677 is a once-daily oral capsule that lifts growth hormone and IGF-1 around the clock and carries the most human data of any GH secretagogue; ipamorelin is an injectable, highly selective peptide that delivers short, pulsatile GH bursts that feel cleaner, with far less water retention and appetite drive. Pick MK-677 for convenience and a steady all-day signal; pick ipamorelin for a more physiologic, better-tolerated profile you are willing to inject.
Most "ipamorelin vs MK-677" pages stop at a mechanism table. We add the signal no competitor has: among our users who logged both, which direction people actually switch, how many run them in parallel, and how the day-to-day side effects compare in real reports. The trial record tells you what is possible; the community data tells you what people choose once they have lived with the puffiness, the appetite, and the daily routine of each. For the full science on either molecule, we link up to its dedicated guide so this page stays a clean decision hub, and for the wider field see our roundup of the best peptides for muscle growth.
Head-to-head
Edge: MK-677 — by a slim margin
The real choice here is route and rhythm: MK-677 is a once-daily oral capsule that raises GH and IGF-1 around the clock (and has the most human data of any GH secretagogue), while ipamorelin is an injectable, highly selective, pulsatile GHRP that more closely mimics natural GH release with fewer water-retention and appetite effects. Our community moat (adoption split, co-tracking, and net switch direction) is the headline signal; the fit-score radar is the secondary editorial 'why'. Both are research compounds, not FDA-approved.
Overall fit score
By dimension
Side by side
| Ipamorelin | MK-677 | |
|---|---|---|
| Class | Selective GHRP (pentapeptide) | Non-peptide oral ghrelin-receptor agonist / GH secretagogue |
| Route | Subcutaneous injection | Oral capsule |
| Half-life / dosing rhythm | ~2 hours; pulsatile, often 1-2x daily | ~24 hours; once-daily, raises GH/IGF-1 around the clock |
| Human data depth | Thin, short-term (mostly single-dose GH-release studies) | Most human data of the GH secretagogues (Nass 2008 + frailty/Alzheimer's trials, the latter failed) |
| Water retention / appetite | Minimal; selective, little appetite effect | Notable water retention + sharply increased appetite |
| Insulin sensitivity / glucose | Largely neutral in short-term reports | Transient decrease in insulin sensitivity, raised fasting glucose |
| FDA status | Not approved (research compound) | Not approved (failed its trials; never marketed) |
| Community adoption (illustrative app data) | 37% (864 of 2,336 pair users) | 63% (1,472 of 2,336 pair users) |
Educational. These are research compounds, not FDA-approved, with limited or no human trial data; this is not medical advice and not a claim that either is effective or safe. Community usage/switch figures are illustrative ProtocolPlus app data. Verify everything with a clinician.
Key Takeaways
- The real difference is route and rhythm. MK-677 is an oral capsule with a roughly 24-hour half-life, so one daily dose keeps GH and IGF-1 elevated around the clock. Ipamorelin has a roughly 2-hour half-life and is injected, producing short pulses that more closely mimic natural GH release.
- MK-677 has the most human data of any GH secretagogue, including a 2-year older-adult trial (Nass 2008) showing raised GH/IGF-1 and lean mass. It was still never FDA-approved and missed its frailty and Alzheimer's endpoints. Ipamorelin's human data is thin and short-term.
- Water retention, appetite, and glucose are the MK-677 trade-offs. The continuous signal commonly drives fluid retention and a sharp appetite increase, plus a transient drop in insulin sensitivity and higher fasting glucose. Ipamorelin is selective and largely avoids these.
- What our community does: among ProtocolPlus users tracking these two, the split is about 63% MK-677, 37% ipamorelin (MK-677 wins on oral convenience), but the net switch leans slightly toward ipamorelin, usually when water retention or appetite pushes people off MK-677. A usage signal, not proof one is better.
- Neither is FDA-approved. Both are research compounds; "dosing" here means what was used in studies, not a recommendation.
The signature difference: oral all-day vs injected in pulses
Before any benefit or side effect, understand the one thing that drives all the others: how each compound shapes your growth hormone over a day. MK-677's roughly 24-hour half-life means a single oral capsule keeps GH and IGF-1 raised more or less continuously. Ipamorelin's roughly 2-hour half-life means each injection produces a short spike that fades, closer to the body's own pulsatile rhythm. That single mechanical fact is why MK-677 tends to build more water retention and appetite (a sustained signal) while ipamorelin feels cleaner (brief bursts), and it is why the two are not interchangeable despite both raising GH.
Ipamorelin vs MK-677 at a glance
Here is the side-by-side before we go deep. MK-677 leads on convenience, all-day coverage, and depth of human data; ipamorelin leads on a cleaner, more selective profile. Everything below this table explains the why.
| Dimension | Ipamorelin | MK-677 (Ibutamoren) |
|---|---|---|
| Drug class | Selective GHRP (pentapeptide) | Non-peptide oral ghrelin-receptor agonist |
| Route | Subcutaneous injection | Oral capsule |
| Half-life / rhythm | ~2 h; pulsatile, often 1-2x daily | ~24 h; once-daily, all-day elevation |
| Human data depth | Thin, short-term | Most of any GH secretagogue (Nass 2008 + frailty/Alzheimer's, the latter failed) |
| Water retention / appetite | Minimal | Notable water retention + increased appetite |
| Insulin sensitivity / glucose | Largely neutral (short term) | Transient drop in sensitivity, raised fasting glucose |
| FDA status | Not approved (research) | Not approved (failed trials, never marketed) |
| Community adoption | 37% (864 users) | 63% (1,472 users) |
The two places the decision genuinely flips are route/convenience (MK-677) and side-effect cleanliness (ipamorelin), so most of the real choice comes down to which of those you weight more.
What does the ProtocolPlus community actually do between the two?
This is the part no trial and no competitor page can give you: among users who have logged both, which way do people move? Trial data tells you what each compound can do in a controlled study; it cannot tell you what real people decide after they have felt the bloat, the hunger, and the daily routine of each. That is the gap our first-party data fills. The short version is that MK-677 is the larger camp on convenience, but the net switch leans the other way, toward ipamorelin, mostly driven by water retention and appetite.
Three numbers carry the story, all from ProtocolPlus app data among the roughly 2,336 users tracking one of these two:
- Adoption split: ~63% MK-677 (1,472 users), ~37% ipamorelin (864 users). MK-677 is the larger camp, and the oral, once-daily format is the obvious reason: no needles, one capsule, all-day coverage.
- Co-tracking: ~22% (about 514 users) log both. That is a meaningful overlap of people comparing the two, transitioning between them, or running an oral base alongside injectable pulses.
- Net switch leans toward ipamorelin (~0.66:1). About 18% of ipamorelin users (roughly 156) later moved to or added MK-677, while about 16% of MK-677 users (roughly 236) moved to or added ipamorelin. The net flow, around 80 users, points to ipamorelin, the opposite direction from the adoption lead.
That split, MK-677 winning adoption while ipamorelin wins the net switch, is the whole story in two numbers. People reach for the convenient oral option first; a meaningful share then trade some convenience for the cleaner profile once the water retention and appetite become annoying.
Which way people switch (and why it is not unanimous)
The flows are nearly balanced, which is itself the point: this is not a runaway in either direction. The slightly larger pull toward ipamorelin matches what users describe, MK-677's all-day signal is convenient but brings puffiness and relentless hunger that some people tire of, so they trade the oral capsule for the cleaner injectable. The reverse pull, ipamorelin users adding or moving to MK-677, is almost always about convenience: they are tired of injecting and want a once-daily pill, or they want the around-the-clock IGF-1 elevation that pulses do not provide. Switching here is not a verdict that one is better; it is people optimizing for the trade-off that bothers them most.
Route and convenience: the everyday lever
The one-sentence answer: for most people the deciding practical factor is not potency but whether you will inject, and MK-677 wins on convenience while ipamorelin wins on a more natural signal. This is the dimension that actually drives the adoption split above.
MK-677 is taken as a single oral capsule, typically once daily, and its roughly 24-hour half-life means that one dose sustains the effect across the whole day and night. Ipamorelin must be injected subcutaneously, and because its half-life is only around 2 hours, getting consistent coverage usually means injecting once or twice a day with insulin-style syringes and reconstituted vials. For someone needle-averse or wanting the simplest possible routine, that difference alone often settles it. The flip side is that the oral, sustained route is exactly what produces MK-677's heavier side-effect load, while ipamorelin's brief pulses are what keep its profile clean. Convenience and cleanliness sit on opposite ends of the same lever. For the full administration detail on each, see the ipamorelin guide and the MK-677 guide.
The evidence case: what the human data actually shows
The one-sentence answer: MK-677 has, by a wide margin, the most human data of any GH secretagogue, while ipamorelin's human evidence is thin and short-term, so this dimension clearly favors MK-677 even though its headline trials failed their primary goals.
MK-677 has been studied in real clinical trials. The most cited is a 2-year randomized trial in healthy older adults (Nass et al., 2008), where once-daily oral MK-677 raised GH and IGF-1 toward levels seen in younger adults and increased lean body mass, though it did not improve strength or function and was accompanied by raised fasting glucose and reduced insulin sensitivity. Separate programs tested it for frailty in older adults (the Murphy work) and, most prominently, in a large Alzheimer's disease trial, both of which failed to meet their primary endpoints. That failure is why MK-677 was never approved or marketed. The takeaway is nuanced: MK-677 reliably moves the GH/IGF-1 numbers in humans, but it never proved a meaningful clinical benefit in the conditions it was developed for.
Ipamorelin, by contrast, is supported mostly by short, single-dose pharmacology studies showing it selectively triggers GH release with little effect on cortisol or prolactin, plus animal data. There is no long-term human outcomes trial comparable to MK-677's. So if "depth of human evidence" is your yardstick, MK-677 leads, with the heavy caveat that more data is not the same as proven benefit, and the data it does have flagged real metabolic downsides.
There is a useful way to read this asymmetry. MK-677's evidence answers the question "does it reliably raise GH and IGF-1 in humans, and is that safe enough to keep taking?" and the honest answer is yes to the first part, with documented metabolic costs, and a clear no to the harder question of whether those raised numbers translate into a meaningful clinical outcome. Ipamorelin's evidence base simply has not been built out far enough to answer either question at the same depth. That does not make ipamorelin worse; it makes it less studied. For someone weighing the two, the practical reading is that you can predict MK-677's effects, including the unwanted ones, with more confidence, while ipamorelin is a cleaner-looking but less-charted option. Neither track record amounts to proof of benefit, which is exactly why both remain research compounds rather than approved drugs.
Water retention, appetite, and glucose: the MK-677 trade-offs
The one-sentence answer: ipamorelin is the cleaner-feeling compound, while MK-677's continuous signal commonly brings water retention, a sharp appetite increase, and a transient hit to insulin sensitivity, and this is the most common reason people switch off it.
Because MK-677 raises GH and IGF-1 around the clock, it tends to drive fluid retention (puffiness, sometimes joint stiffness) and a notable rise in appetite, which is welcome for someone trying to gain but unwelcome for most. It also reduces insulin sensitivity and raises fasting glucose, an effect documented in the older-adult trial data, which matters for anyone with metabolic risk. Ipamorelin's selectivity and brief pulses largely avoid this trio: users describe little water retention and minimal appetite change. That contrast is the engine behind the net switch toward ipamorelin in our community data.
A transparency note worth stating plainly: our structured side-effect dataset only overlaps on two effects for this pair (vivid dreams and headache), so the chart above is a partial picture, not a complete side-by-side. On both tracked effects ipamorelin reports lower, and the vivid-dreams gap (4% vs 22%) fits MK-677's known ghrelin-driven, sleep-active profile. The water retention, appetite, and glucose effects described above come from the trial literature, not from a head-to-head frequency in our data, which is why we describe them qualitatively rather than charting a number. For the complete tolerability breakdown and red-flag list, read ipamorelin side effects and MK-677 side effects. This page does not duplicate them.
How fast do they work, and what does the timeline feel like?
The one-sentence answer: neither is an overnight switch, but the two front-load very different signals, MK-677's most obvious early effects (appetite, water, sleep) show up within days, while the lean-mass and recovery changes both compounds are used for unfold over weeks to months.
On MK-677, the first thing most people notice within the first week is not muscle but the side-effect signature: a sharper appetite, some fluid retention or puffiness, and often more vivid dreams or deeper sleep, all consistent with its continuous ghrelin-receptor signal. The body-composition changes that the older-adult trial measured (raised IGF-1, increased lean mass) accrued over months of daily dosing, not days. Ipamorelin's pulses are subtler day to day; there is no appetite surge or bloat to announce themselves, so the early experience is quieter, and any lean-mass or recovery benefit is likewise a multi-week process. The practical implication for choosing is that MK-677 gives you fast, unmistakable feedback that "something is happening," which some people find reassuring and others find off-putting, while ipamorelin asks for more patience and a longer judging window. In both cases the honest expectation is steady, unglamorous change over weeks to months, not a quick transformation, and any timeline you read should be treated as approximate given how thin the controlled human data is.
Cost and access: an honest data gap
The one-sentence answer: in our community data we have a cost figure for ipamorelin but not a reliable one for MK-677, so we will not invent a head-to-head price comparison.
For ipamorelin, ProtocolPlus cost data shows a median around $1.60 per dose (vials roughly $25 to $55, about 25 doses per vial). We do not have a comparable per-dose cost on file for MK-677, so there is no honest cheaper-per-dose verdict to give, and we are not going to fabricate one. Both are sold only as unregulated research-grade supply, where purity and labeling vary widely, which matters more than a few dollars either way. Treat any price you see as a directional signal, not a quote, and weigh supply quality and route convenience above raw cost.
The editorial scorecard (the "why," not the verdict)
The fit-score radar below rates each compound 1 to 5 on six dimensions. With equal weighting MK-677 edges ahead (60 vs 57): it leads on evidence depth, accessibility (oral), and speed, while ipamorelin leads on safety/tolerability and cost. That narrow margin is the honest summary, and it reflects evidence quantity and convenience, not a claim that MK-677 is the better choice for you. The community usage and switch data above, not this radar, is the headline signal, and your own priorities decide which dimension matters most.
Choose ipamorelin if... / Choose MK-677 if...
The decision rarely needs a coin flip. These two cards cover the great majority of cases.
Choose ipamorelin if:
- You want the cleaner, more physiologic option and are fine with subcutaneous injections.
- You are sensitive to water retention, puffiness, or appetite spikes and want to avoid them. This is the most common reason people move here in our data.
- You care about insulin sensitivity and fasting glucose and prefer a largely neutral profile.
- You want pulsatile GH bursts that mimic natural release rather than a 24-hour elevation.
Choose MK-677 if:
- You want a once-daily oral capsule and will not inject. This is the single biggest driver of its adoption lead.
- You want sustained, around-the-clock GH and IGF-1 elevation rather than short pulses.
- You value having the largest human-data base of any GH secretagogue, even though those trials failed their endpoints.
- You can tolerate, or actively want, increased appetite and accept the water-retention and glucose trade-offs.
The honest verdict
If you will inject and you value a clean profile, ipamorelin is the better-tolerated, more physiologic choice, and our community quietly votes that way with its feet: the net switch leans toward it despite MK-677 being the more popular first pick. If convenience is decisive, you will not inject, or you want all-day IGF-1 coverage and the reassurance of more human data, MK-677 is the rational pick, as long as you go in expecting water retention, appetite, and a glucose hit. Neither is FDA-approved, MK-677's own trials failed their primary goals, and ipamorelin's human evidence is thin, so this is a decision to make with a clinician, not from a comparison page alone.
To make it concrete, here is how the decision usually lands by situation:
- Will not inject, wants simplest routine: MK-677 (oral, once daily).
- Sensitive to water retention or appetite: ipamorelin; this is the community's most common reason to switch.
- Wants around-the-clock IGF-1 elevation: MK-677's long half-life is built for that.
- Prioritizes insulin sensitivity / fasting glucose: ipamorelin (largely neutral short-term).
- Wants the deepest human data, eyes open about failed trials: MK-677.
- Wants the cleanest, most physiologic GH signal: ipamorelin's pulses.
For adjacent matchups, see CJC-1295 vs ipamorelin and hexarelin vs ipamorelin. For the full single-compound science, see the ipamorelin guide and the MK-677 guide.
Frequently Asked Questions
Sources
- Nass R, Pezzoli SS, Oliveri MC, et al. "Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults" (MK-677, 2-year RCT). Annals of Internal Medicine, 2008;149(9):601-611. DOI 10.7326/0003-4819-149-9-200811040-00003. Retrieved 2026-06-18. https://www.acpjournals.org/doi/10.7326/0003-4819-149-9-200811040-00003
- Murphy MG, Weiss S, McClung M, et al. "Effect of Alendronate and MK-677 on Bone Mineral Density and Biochemical Markers in Older Adults." Journal of Clinical Endocrinology & Metabolism, 2001;86(3):1116-1125. Retrieved 2026-06-18. https://academic.oup.com/jcem/article/86/3/1116/2848264
- Sevigny JJ, Ryan JM, van Dyck CH, et al. "Growth Hormone Secretagogue MK-677: No Clinical Effect on AD Progression in a Randomized Trial." Neurology, 2008;71(21):1702-1708. DOI 10.1212/01.wnl.0000335163.88054.e7. Retrieved 2026-06-18. https://www.neurology.org/doi/10.1212/01.wnl.0000335163.88054.e7
- Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the First Selective Growth Hormone Secretagogue." European Journal of Endocrinology, 1998;139(5):552-561. DOI 10.1530/eje.0.1390552. Retrieved 2026-06-18. https://pubmed.ncbi.nlm.nih.gov/9849822/
- ProtocolPlus. "Community head-to-head data: ipamorelin vs MK-677" (head-to-head/ipamorelin__mk-677.json). First-party app data, 2026. n ~ 2,336 users tracking one of the two. Usage and switching signal, not a clinical efficacy verdict. Note: structured side-effect overlap is limited to two effects, and no MK-677 per-dose cost is on file.